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Abstract
Background: Anecdotal information and case reports suggest that intravenously administered vitamin C is used by
Complementary and Alternate Medicine (CAM) practitioners. The scale of such use in the U.S. and associated side effects are
unknown.
Methods and Findings: We surveyed attendees at annual CAM Conferences in 2006 and 2008, and determined sales of
intravenous vitamin C by major U.S. manufacturers/distributors. We also queried practitioners for side effects, compiled
published cases, and analyzed FDA’s Adverse Events Database. Of 199 survey respondents (out of 550), 172 practitioners
administered IV vitamin C to 11,233 patients in 2006 and 8876 patients in 2008. Average dose was 28 grams every 4 days,
with 22 total treatments per patient. Estimated yearly doses used (as 25g/50ml vials) were 318,539 in 2006 and 354,647 in
2008. Manufacturers’ yearly sales were 750,000 and 855,000 vials, respectively. Common reasons for treatment included
infection, cancer, and fatigue. Of 9,328 patients for whom data is available, 101 had side effects, mostly minor, including
lethargy/fatigue in 59 patients, change in mental status in 21 patients and vein irritation/phlebitis in 6 patients. Publications
documented serious adverse events, including 2 deaths in patients known to be at risk for IV vitamin C. Due to confounding
causes, the FDA Adverse Events Database was uninformative. Total numbers of patients treated in the US with high dose
vitamin C cannot be accurately estimated from this study.
Conclusions: High dose IV vitamin C is in unexpectedly wide use by CAM practitioners. Other than the known complications
of IV vitamin C in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency, high dose intravenous
vitamin C appears to be remarkably safe. Physicians should inquire about IV vitamin C use in patients with cancer, chronic,
untreatable, or intractable conditions and be observant of unexpected harm, drug interactions, or benefit.
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Introduction
Among the most enduring of alternative medical treatments,
vitamin C (ascorbic acid, ascorbate) is also one of the most popular.
In 2007, it was the most widely sold single vitamin, with sales of 884
million dollars in the US1 [1]. Independent of its use to treat the
deficiency disease scurvy, vitamin C has been used by non-
mainstream physicians orally and parenterally for more than 60
years as a therapeutic agent [2–7]. Oral vitamin C is widely used by
the public to prevent or treat infections, especially the common cold
[8]. In one of its more controversial applications, gram doses of
vitamin C were promoted by the two-time Nobel Laureate Linus
Pauling as a cancer treatment agent [9,10]. Anecdotal evidence led
us to posit that intravenous (IV) vitamin C is still used by
Complementary and Alternative Medicine (CAM) practitioners to
treat diverse conditions including infections, autoimmune diseases,
cancer and illnesses of uncertain origin [11–13].
Despite its purported popularity, the extent of use of IV vitamin
C is unknown. Its use in CAM has not been well publicized by
practitioners and their patients, and is likely to be unrecognized by
mainstream physicians. Benefits if any and especially side effects of
such use may be unreported or under-reported. It is useful to know
if high dose IV vitamin C therapy is widely used, and if so how and
for what, so that conventional physicians can improve patient care
by identifying any ill effects or drug interactions, and reporting
benefit if any.
New knowledge has elucidated possible mechanisms of action of
IV vitamin C and for the first time made therapeutic effects
biologically plausible [14]. It is now known that IV but not oral
administration of vitamin C produces pharmacologic plasma
concentrations of the vitamin [15,16]. Past studies used oral and/
or IV routes inconsistently, making such studies, in retrospect,
flawed and difficult to interpret [17]. Recent in vitro experiments
indicated that vitamin C only in pharmacologic concentrations
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was via hydrogen peroxide formation [18]. In vivo animal data
indicated that hydrogen peroxide was produced selectively in
extracellular fluid around normal and tumor tissues by pharma-
cologic vitamin C concentrations [19,20]. At these concentrations,
vitamin C slowed tumor growth [20,21]. Pharmacologic vitamin C
concentrations produced in animals by parenteral administration
were reproduced in patients in a recent phase I clinical trial [16].
Because of the new interest in IV vitamin C, coupled to need to
characterize use and uncover side effects, we surveyed CAM
practitioners anonymously. We also searched for side effects of IV
vitamin C administration in the published medical literature and
in the Food and Drug Administration (FDA) adverse events
database, and estimated sales volumes of IV vitamin C
preparations.
Our study obtained quantitative information that substantiated
previous anecdotal reports. Despite unexpected wide use, we
found side effects of vitamin C were surprisingly few when patients
were properly screened. The findings in this paper will alert
conventional practitioners about unrecognized wide use of IV
vitamin C, will remind them to query patients about such use, and
may help to uncover either unexpected adverse events or benefit
and spur further research in this area.
Methods
Survey Methods
The study was reviewed by the Human Subjects Committee/
Institutional Review Board at the University of Kansas Medical
Center. The survey was categorized as an exempt study. It
contained no personal identifiers; therefore informed consent was
not necessary under exempt status and was not obtained. Survey
forms were distributed to practitioners attending a conference on
CAM in 2006 and 2008. Participants were requested to return
completed survey forms before the end of each conference.
Participants were asked whether they used high dose IV vitamin C
during the preceding 12 months, and if so, to detail its use by
answering specific questions in the survey form (see Survey S1 for
the survey form used). It was not possible to identify the
respondent from the survey form or survey data. The same form
was used in both years, with an additional line on the 2008 form
inquiring whether the respondent had also responded in 2006 (See
Survey S1).
Vitamin C doses sold
The major manufacturers/importers in the US of vitamin C
preparations that can be administered IV were contacted by
telephone. Data on annual sales of vitamin C in the US were
obtained with the understanding that the names and sales figures
of individual companies would not be linked nor made public.
Side effects of high dose IV vitamin C
We searched the Adverse Events Reporting System, a database
of drug side effects maintained by the Food and Drug
Administration (FDA). Data from 20 consecutive quarters
available from 2004–2008 were queried. We also searched for
side effects in publications on therapeutic use of high dose IV
vitamin C. We searched Medline, Web of Science (ISI Thompson)
and Scopus databases for papers in English that reported IV
vitamin C administration in humans. Several different search
terms and possible variants of each search term were used to
capture the maximum number of papers. Papers reporting oral
vitamin C treatment only, or those using IV doses of 1g or less,
were excluded. Because vitamin C is sometimes administered IV
in patients undergoing hemodialysis, there are many published
studies in this area. A separate search was conducted for papers
reporting these to ensure that these were excluded from our
analysis. IV administered vitamin C is also used to study the acute
effects of antioxidants or of vitamin C itself on metabolism and
physiology, particularly on cardiovascular and endothelial reac-
tivity. This does not constitute a therapeutic use of vitamin C.
Hence publications reporting these were identified and removed
from the search results. Separately, we searched the same
databases for specific reports of side effects of IV administered
vitamin C and followed up references and cited papers. From
papers so collected, we manually eliminated duplicate citations
and those that did not meet the above criteria. From the
remaining reports, adverse reactions attributable to IV adminis-
tered vitamin C were noted.
Results
Survey response
We distributed 300 survey forms in 2006 to attendees at their
annual CAM conference. 106 forms were returned, a response
rate of 35%. In 2008, 250 survey forms were distributed and 93
completed forms were returned, a response rate of 37%. Of the
2008 respondents, 22 (24%) had previously responded in 2006. An
unknown number of conference attendees were not practitioners
but spouses, researchers or industry representatives who did not
return survey forms, reducing response rates.
Vitamin C usage
Of 199 total respondents for 2006 and 2008: 172 practitioners
administered vitamin C; 27 did not use IV Vitamin C; 48
practitioners treated more than 100 patients each per year; and 5
treated more than 1000 patients each per year (Figure 1A, B).
11,233 patients received IV vitamin C in 2006 and 8876 in 2008
(figure 1A, B). On average, each patient received 22 treatments
(Table 1). Treatments occurred at a mean of once every 4 days,
each at a mean dose of 28 grams (Table 1). Doses used were as low
as 1gram or as high as 200grams, with a similar wide range for
each of the parameters queried. Based on dosing vials of 25g/
50ml, estimated total yearly dosing vials administered were
318,539 in 2006 and 354,647 in 2008. Estimated total number
of dosing vials sold was independently obtained from the major
manufacturers of vitamin C in the U.S. Total dosing vials of IV
vitamin C sold in the United States were approximately 750,000 in
2006 and 855,000 in 2008 (Table 1).
Seventy seven percent of respondents reported the numbers of
patients treated for broad indications, labeled as infection (44%),
cancer (19%) or other conditions (37%) (Table 2). Numbers of
practitioners who listed specific indications for treatment are
shown in figure 2. Practitioners listed fatigue as the most common
specific single indication for treatment in 2006, and breast cancer
in 2008. There were a large number of indications for which less
than four practitioners used high dose IV vitamin C (Table S1).
Adverse effects
Adverse events reported by survey respondents were minor
(Table 3). No side effects were reported for 9227 patients while 59
were reported to have lethargy or fatigue. A single practitioner
listed change in mental status in 10% of his patients (20 patients)
but provided no details. One patient with pre existing renal
impairment and cancer metastases to kidneys was reported to have
developed unconfirmed renal failure. Some practitioners reported
side effects without reporting patient numbers. The most common
of these side effects were lethargy or fatigue (reported by 27
IV Vitamin C Use
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vomiting (by 9 practitioners). Other reported side effects are listed
in table 3. Less commonly reported adverse effects are listed in
Table S2.
Data obtained from the FDA Adverse Events Reporting System
database for 20 consecutive quarters indicated that 77 patients
treated with 0.2–1.0 gram doses of IV vitamin C had reported
adverse events (Table 4). However, all patients either had serious
or life-threatening systemic illnesses, and/or were receiving many
potentially toxic drugs (i.e. cancer therapeutics) in addition to IV
vitamin C (for details, see Table S3). Some individual patients
appear to have been reported multiple times (see Table S3). In
comparison to CAM practitioners, the dose of vitamin C
administered was very low (1 gram or less). In no case could we
exclude multiple confounding factors as the cause of the reported
adverse effects (Table 4). Whether vitamin C caused or
contributed to these side effects cannot be determined from the
available data.
Through searching published literature (see methods for details),
187 papers were found on the use of high dose IV vitamin C,
including papers that reported side effects. There were three cases
of renal failure, all in patients with pre existing renal impairment
[22,23], [24]. Two patients with glucose 6 phosphate dehydroge-
nase deficiency developed hemolysis [25,26] (Table 5).
Practitioner Demographics
86% of practitioners were physicians (Table 6) and most
patients were treated at for-profit centers. Some practitioners
did not provide requested demographics data. Therefore, the
numbers given in this table do not tally with the total number of
survey respondents. (For detailed demographic information, see
Table S4).
Figure 1. Cumulative total and the distribution of patients treated among the survey respondents. Practitioners were grouped
according to the number of patients whom they treated with IV vitamin C in the preceding twelve months. For ease of display, number of patients
were divided into arbitrary ranges which are shown on the X axis. The number of practitioners who treated the specified number of patients are
shown on the Y axis. Patients were unevenly distributed among survey respondents. In 2006, out of 106 practitioners who responded to the survey,
13 did not use high dose IV vitamin C, 30 respondents treated more than 100 patients each, and 3 treated 1000 or more patients (Fig 1A). For 2008,
the corresponding numbers were 93, 14, 18 and 2 respectively (Fig 1B). Cumulative total of patients treated by all practitioners are shown as line
diagrams (scaled to Y axis on right).
doi:10.1371/journal.pone.0011414.g001
Table 1. Details of high dose IV vitamin C use by survey respondents for the years 2006 and 2008.
2006 2008
Mean Median Range Mean Median Range
Dose (g/treatment) 28 31 1–200 28 50 1–200
Number of treatments per patient 19 16 1–80 24 16 1–80
Number treated by one practitioner 121 40 1–1150 112 40 1–3000
Duration of treatments (min) 105 90 2–1440 81 90 1–900
Frequency of treatments (once every so many days) 4 3.5 1–7 4 2 1–7
Lowest dose (g/treatment) 12 9 1–60 17 15 1–75
Highest dose (g/treatment) 79 75 5–200 87 95 20–200
Infusion rate (g/min) 0.89 0.5 0.03–25 0.525 0.5 0.028–2.5
Total number of vials of vitamin C used (25g/50ml) (Calculated from survey data) 318,539 354,647
Total number of vials of vitamin C sold by companies in the US (25g/50 ml) 750,000 855,000
Vitamin C is supplied in 50 ml bottles containing 25grams. Estimated total number of doses (bottles) used each year was calculated as the cumulative sumo fe a c h
practitioners’ number of patients6that practitioners’ average dose in bottles6that practitioner’s average number of doses per patient.
doi:10.1371/journal.pone.0011414.t001
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The data here show that 11,233 and 8876 patients received IV
vitamin C over two periods of one year each, with a mean number
of infusions per patient of 19–24 and a mean dose of
approximately 28 grams per patient. We estimate that survey
respondents used approximately 318,539 and 354,647 dosing units
of vitamin C each year. These numbers account for less than half
of the doses of vitamin C doses sold within the United States for
the matching year. Considered together, these data indicate that
use of IV vitamin C was both substantial and probably
underestimated. This is one of the first papers to document
previously unrecognized and widespread use of a CAM agent
administered IV. To our knowledge, only two other CAM
therapies are used IV. The first, chelation therapy, is also used
in standard medical practice [27]. The second, an IV vitamin and
mineral mixture termed the Myer’s cocktail, has variable
components, has had little formal investigation, and contains less
than 5 grams of vitamin C [28,29]. Further, there have been few
surveys of CAM practitioners, as opposed to surveys of patients.
There were minimal adverse effects reported, which was also the
case in the published literature. Exceptions were for patients with
pre-existing renal insufficiency/failure or glucose 6-phosphate
dehydrogenase (G6PD) deficiency, both known to predispose to
vitamin C toxicity [30]. Adverse events reported to the FDA could
not be interpreted due to confounding factors.
Figure 2. Number of practitioners who used intravenous vitamin C for various conditions. X axis shows the number of practitioners who
used intravenous vitamin C to treat each of the conditions listed on the Y axis. Blue bars denote infections, red bars denote cancers, and green bars
denote other indications. Data for 2006 (solid bars) and 2008 (hatched bars) show that intravenous vitamin C was most often used to treat infections
and cancer. Indications for which less than four practitioners used high dose intravenous vitamin C are listed in Table S1.
doi:10.1371/journal.pone.0011414.g002
Table 2. Indications for treatment with high dose IV vitamin C.
Year 2006 2008
Total number of patients treated 11233 8876
Number of patients with data available 9481 5928
Number of Patients with Infection 4587 2264
Cancer 1379 1509
Other Conditions 3515 2155
Some respondents did not list the number of patients treated for each of the
conditions for which they used intravenous vitamin C treatment. Therefore, the
data do not provide indications for treatment for all patients who received IV
vitamin C.
doi:10.1371/journal.pone.0011414.t002
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vitamin C was shown to significantly decrease polio virus
infections in primates [31,32]. Although these findings were not
repeatable [33,34], one practitioner treated thousands of patients
with parenteral vitamin C, primarily for infections, and popular-
ized its use [2,3,5]. Such reports probably were a basis for
continued use of parenteral vitamin C by other CAM practitioners
[6,7,35]. Independently, others postulated that vitamin C could be
useful in cancer treatment by enhancing or strengthening collagen
and intercellular matrix synthesis and thereby decreasing metas-
tases [36,37]. Ewan Cameron, joined by Nobelist Linus Pauling,
reported in retrospective case series that oral and IV vitamin C
might benefit patients with advanced cancers [9,10]. Placebo-
controlled double blinded clinical trials at the Mayo Clinic showed
no efficacy [38–40] but CAM practitioners continued to use IV
vitamin C [11,13,35], consistent with our survey results.
Pharmacokinetics evidence [15,41,42] now reveals that the
exclusively oral vitamin C doses used in the Mayo studies would
have produced peak plasma concentrations of approximately
0.2 mM, while the same dose given IV would produce peak
plasma concentrations approximately 25 fold higher [15].
Pharmacologic doses of vitamin C given IV may produce drug
effects in many body tissues, mediated by hydrogen peroxide
formation in extracellular fluid but not blood [18–20]. Emerging
clinical data are consistent with plausibility [43] and safety [16],
but whether there is benefit or harm in humans can only be
addressed by rigorous clinical trials.
IV vitamin C administered in gram doses can cause serious side
effects in some patients. A metabolic end-product of vitamin C
metabolism is oxalate, and oxalate nephropathy has been reported
in patients with renal impairment given gram doses of IV vitamin
C [22–24]. Prolonged treatment with vitamin C increases plasma
oxalate concentrations in patients with renal failure [44] and
results in increased urinary oxalate in patients receiving total
parenteral nutrition [45], although in these patient groups the
consequences of hyperoxalemia are unknown. Patients with
glucose 6-phosphate dehydrogenase deficiency can develop
intravascular hemolysis when gram doses of vitamin C are given
IV [25,26]. Vitamin C, even with oral dosing, might induce
hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria
[46,47]. A recent phase one study of high dose IV vitamin C in
patients with advanced cancer did not find any serious side effects
[16]. Exclusion criteria for the phase I study included renal failure
and glucose-6-phosphate dehydrogenase deficiency. Recently, a
study in mice reported decreased efficacy of cancer chemother-
apeutic agents with parenteral dehydroascorbic acid, a metabolite
of vitamin C [48]. Dehydroascorbic acid cannot be detected in
human blood or tissues, is not commercially available for
parenteral use nor used by CAM practitioners, is toxic at high
concentrations [49,50], and should not be administered parenter-
ally in humans.
No definitive serious adverse events were reported by survey
respondents. Despite the anonymity of the survey, practitioners
may have been reluctant to describe adverse events. Whether IV
vitamin C is safe for general use remains to be determined.
Because of the possibility of unrecognized side effects or of drug
interactions, practitioners should enquire whether their patients,
especially those with chronic, intractable or difficult to treat
conditions, are receiving high dose IV vitamin C treatment
elsewhere. Physicians should be alert to potential interactions of
high dose vitamin C not only with conventional medicines but also
with CAM treatments. An example is the case of exacerbated,
severe cyanide poisoning in a patient on concurrent treatment
with high dose oral vitamin C and Amygdalin (laetrile, a metabolic
product of which is cyanide) [51].
Table 3. Adverse events reported with IV vitamin C use in the
survey for the years 2006 and 2008.
Number of Patients
Complication 2006 2008
None Described 5349 3878
Lethargy/Fatigue 10 49
Local Vein Irritation 3-
Phlebitis 3-
Kidney Stone (oxalate) -1
Kidney Stone (urate) -1
Kidney Stone (unspecified) 2-
Hemolysis 2-
Elevated Blood Glucose 2-
Muscle Cramps 1-
Headache 1-
Change in Mental Status 12 0
Nausea/Vomiting 1-
Flu Like Syndrome 1-
Renal Failure -1 *
Syncope -1
Pain at Tumor -1
No Data 5857 4924
Data included in the table represent only those practitioners who reported
exact patient numbers.
*Described as ‘‘not confirmed (possible). Patient had partial renal failure and
cancer metastases to kidneys.’’
Data on practitioners who reported adverse events but did not report the
number of patients affected are detailed below as: side effect (with the number
of practitioners who reported each side effect in parenthesis).
For the year 2006: lethargy/fatigue (9), local vein irritation (3), nausea/vomiting
(2), hypoglycemia (2), allergy (2), phlebitis (1), cellulitis (1), hematuria (1), dry
mouth (1), Herxheimer reaction (1), localized thrombosis (1), and syncope (1).
For the year 2008: lethargy/fatigue (9), nausea/vomiting (6), local vein irritation
(4), headache (3), phlebitis (3), heartburn (1), dizziness (1), venosclerosis (1), mild
palpitation (1), and cold (1), dizziness (1), ‘‘initiation of mem occasionally’’ (1),
and other (1).
doi:10.1371/journal.pone.0011414.t003
Table 4. Adverse effects reported to the Food and Drug
Administration (FDA) in patients treated with IV vitamin C.
Year
Number of
Cases reported
Dose Range
(g/day)
Can confounders
be eliminated?
2004 15 0.5–1 No
2005 7 0.25–1 No
2006 11 0.2–1 No
2007 11 Not Given No
2008 33 0.5–1 No
When the vitamin C dose was provided as ml, the dose was converted to mg on
the basis that vitamin C is supplied as 0.5gram/ml solution. Some practitioners
did not mention the dose of vitamin C used. The format of the FDA adverse
events database did not permit identification of specific patients, so that the
same patient may have been reported multiple times in the same quarter or in
several quarters, inflating the number of patients with adverse events.
doi:10.1371/journal.pone.0011414.t004
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underestimate use of IV vitamin C. Because our survey was
distributed to participants in a CAM conference, the survey
excluded the vast majority of CAM practitioners. Respondents
who filled in the survey form did so from memory without access
to records, so that the information obtained can only be
considered approximate. The format of the survey questions
may have inadvertently resulted in underestimating vitamin C use,
because the survey questions used ranges, for simplicity. For
example, the highest value listed for numbers of patients treated in
a calendar year was ‘‘.40’’. If practitioners did not specify precise
numbers as requested in subsequent questions, 40 was used as the
number of patients treated, although the true number may have
been higher. That there was only 24% overlap between survey
respondents in 2006 and 2008 provides additional evidence that
community use of IV vitamin C was underestimated. Data
concerning industry sales of IV ascorbate only give approxima-
tions of use. On one hand, because not all units sold would have
been used, use may be overestimated. Conversely, other smaller
companies and compounding pharmacies may supply parenteral
vitamin C but were not included in the survey. Therefore, the total
number of vials sold may also be underestimated. The exact
number of doses of parenteral vitamin C used in the US per year
remains unknown. The survey response rate of approx 35%
suggests we underestimated use, and perhaps adverse events. A
reduced response rate may have occurred because some
conference attendees were not practitioners and therefore did
not return survey forms. Because of these uncertainties, the
number of US patients treated with IV vitamin C cannot be
accurately estimated from survey data. Since a primary aim of the
survey was to determine if IV administered vitamin C is in use,
and not a census of patients treated, the response rate does not
detract from the value of the data.
Data obtained on adverse effects from PUBMED and the FDA
also have limitations. Physicians may have not reported compli-
cations because they were not recognized, or were delayed, or
were not attributed to vitamin C. Most practitioners do not report
or publish adverse events. There may be as yet unknown adverse
effects or interactions of IV ascorbate with other drugs. Side effects
Table 5. Adverse effects of vitamin C reported in the literature.
# Type of Side Effect
Patient
Details Vitamin C Dose Clinical Details
Outcome (and
reference)
Pre Vitamin C
Treatment Post Vitamin C Treatment
1 Acute Renal Failure 70 M 2.5g IV61 dose Creatinine 5.0 Flank pain, hematuria. Creatinine 10. Permanent renal
failure(24)
Renal biopsy – Calcium oxalate
crystals in tubular lumen
25 8 F 4 5 g I V 61 dose Nephrotic syndrome Oliguria. Treated with dopamine and
hemodialysis. After first dialysis plasma
vitamin C 15.4mg/dl (0.87mM), oxalate
2.3mg/dl. Intractable ventricular fibrillation. Post
mortem- intra tubular calcium oxalate crystals.
Died(22)
Creatinine 0.8
36 1 M 6 0 g I V 61 dose Metastatic prostate
cancer
Anuric. Creatinine 13.4. Plasma vitamin C
116.2mg/dl (6.6mM). Treated with nephrostomy
and forced diuresis. Renal biopsy - acute tubular
necrosis and extensive oxalate deposition
Recovered(23)
Obstructive uropathy
Creatinine 0.7
4 Hemolysis in Patients with
Glucose-6-Phosphate
Dehydrogenase Deficiency
68 M 80g IV62 days Second degree
burns of one hand
Hemoglobin 5.8. Retics 5.9%. Anuria,
creatinine 13.8. Coma, hemiparesis,
possible intravascular coagulation.
Supportive treatment and hemodialysis.
Died on day
22(25)
53 2 M 4 0 g I V 3 6/wk 20–40g/
day oral61 month
then 80g IV61 dose
HIV Breathlessness, fever, dark urine. Hemoglobin
6.7 Retics 15.6%. Bilirubin 3.16. Conservative
treatment with high fluid intake
Recovered(26)
Normal ranges and units of measurement for laboratory values are: Serum creatinine - mg/dl (normal range 0.6–1.5mg/dl). Hemoglobin g/dl (normal range: male 13–
18g/dl, female 12–16g/dl). Reticulocyte count in % (normal range 0.5–2.5% red cells). Plasma bilirubin- mg/dl (normal range ,1mg/dl). Plasma vitamin C - mg/dl (normal
range 0.6–2 mg/dl).
doi:10.1371/journal.pone.0011414.t005
Table 6. Details of treating practitioners and institutions.
Number of
Practitioners
2006 2008
Characteristics of
Practitioners
Physician (MD) 66 49
Doctor of Osteopathy (DO) 11 12
Doctor of Naturopathy (ND) 88
Nurse 21
Physician’s Assistant (PA) 22
Type of Institution For-Profit organization 81 68
Non-Profit/Other* 74
*Other includes an academic medical center and a tribal medical center.
doi:10.1371/journal.pone.0011414.t006
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factors. All reported patients received other potentially toxic drugs
and/or had other diagnoses that may have been responsible for
the reported adverse effects (see Table S3). Because of the FDA
adverse events format, the same patient was likely to have been
reported multiple times. Because of the low doses of IV vitamin C
in the FDA dataset, it is highly unlikely that any of the reported
adverse effects were due to the vitamin. Despite this, and because
the information available in the FDA database is limited, it is not
possible to accurately determine whether vitamin C caused or
contributed to the reported side effects.
IV vitamin C is already in wide use, and physicians should know
that their patients may seek IV vitamin C treatment in addition to
conventional therapies. Beneficial effects of intravenous vitamin C
on the disease conditions for which it is used are unproven, but
side effects appear to be minor. Physicians should be cognizant of
potential adverse or other unexpected effects, and of unrecognized
interactions with drugs used in conventional and alternative
medicine. CAM practitioners have an obligation to screen patients
and should not administer high dose IV vitamin C to patients with
pre existing renal disease, renal insufficiency or renal failure;
glucose 6-phosphate dehydrogenase deficiency; a history of oxalate
nephrolithiasis; or paroxysmal nocturnal hemoglobinuria. Based
on emerging evidence, vitamin C in pharmacologic concentrations
appears to be a pro-drug for delivery of hydrogen peroxide to the
extravascular space. High dose IV vitamin C appears to have a
positive safety profile, favorable pharmacology, evidence for
mechanism of action, some anti-cancer effects in vitro and in
animals, and widespread use outside conventional medicine with
minimal harm, but without any proven clinical benefit.
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